APA (7th ed.) Citation

JR, T., SW, M., D, N., MA, L., Y, X., RW, S., . . . R, W. (2004). Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. Journal of medicinal chemistry, 47(10), 2405. https://doi.org/10.1021/jm0304515

Chicago Style (17th ed.) Citation

JR, Tagat, et al. "Piperazine-based CCR5 Antagonists as HIV-1 Inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a Potent, Highly Selective, and Orally Bioavailable CCR5 Antagonist." Journal of Medicinal Chemistry 47, no. 10 (2004): 2405. https://doi.org/10.1021/jm0304515.

MLA (9th ed.) Citation

JR, Tagat, et al. "Piperazine-based CCR5 Antagonists as HIV-1 Inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a Potent, Highly Selective, and Orally Bioavailable CCR5 Antagonist." Journal of Medicinal Chemistry, vol. 47, no. 10, 2004, p. 2405, https://doi.org/10.1021/jm0304515.